Close Menu

Luminex

The firm closed its existing debt facility with Silicon Valley Bank and Oxford Finance and plans to use the funds for general corporate purposes and working capital.

The firm also commenced a registered direct offering of $4.4 million and entered into a new $30 million debt facility with NSPH Funding.

The company is preparing for the fourth quarter launch of its Aries sample-to-answer system and assays, as well as its NxTag Respiratory Pathogen Panel.

Infectious disease assays accounted for 64 percent of total assay sales in the quarter.

As a result of the action, the number of Nanosphere's outstanding common shares will be reduced to about 5.9 million from 117.2 million, the firm said.

Building on a recent point-counterpoint in the Journal of Clinical Microbiology, lab directors discuss pros and cons of large MDx panels for infectious disease testing. 

The company aims to seek US and European approval later this year.

Use of the blood culture panel in a community hospital setting led to shorter time to targeted treatment for the patient and a shorter stay in the hospital.

Luminex said its technology will enhance the processing speed and capacity of Assurex's tests.

The firm's shareholders will vote next month on the proposals, which are aimed at getting Nanosphere back in compliance with Nasdaq listing requirements.

Pages

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.